Arthur He
Stock Analyst at HC Wainwright & Co.
(0.54)
# 3,875
Out of 4,751 analysts
50
Total ratings
20.83%
Success rate
-21.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintains: Buy | $5 → $8 | $1.91 | +318.85% | 9 | Jan 27, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $16 | $3.15 | +407.94% | 8 | Jan 13, 2025 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $6.5 | $0.81 | +703.56% | 1 | Jan 13, 2025 | |
| HOOK HOOKIPA Pharma | Downgrades: Neutral | n/a | $1.91 | - | 7 | Jan 10, 2025 | |
| LVTX LAVA Therapeutics | Maintains: Buy | $6 → $2 | $1.00 | +100.00% | 8 | Dec 20, 2024 | |
| ADAP Adaptimmune Therapeutics | Reiterates: Buy | $3.5 | $0.59 | +495.24% | 5 | Nov 19, 2024 | |
| BCAB BioAtla | Downgrades: Neutral | n/a | $0.45 | - | 7 | Nov 13, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $10 | $2.65 | +277.36% | 5 | Nov 13, 2024 |
Adagene
Jan 27, 2025
Maintains: Buy
Price Target: $5 → $8
Current: $1.91
Upside: +318.85%
Solid Biosciences
Jan 13, 2025
Reiterates: Buy
Price Target: $16
Current: $3.15
Upside: +407.94%
Nektar Therapeutics
Jan 13, 2025
Reiterates: Buy
Price Target: $6.5
Current: $0.81
Upside: +703.56%
HOOKIPA Pharma
Jan 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.91
Upside: -
LAVA Therapeutics
Dec 20, 2024
Maintains: Buy
Price Target: $6 → $2
Current: $1.00
Upside: +100.00%
Adaptimmune Therapeutics
Nov 19, 2024
Reiterates: Buy
Price Target: $3.5
Current: $0.59
Upside: +495.24%
BioAtla
Nov 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.45
Upside: -
Prime Medicine
Nov 13, 2024
Reiterates: Buy
Price Target: $10
Current: $2.65
Upside: +277.36%